Aripiprazole

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Aripiprazole and local guidelines before prescribing.

Atypical antipsychotic (partial D2 agonist)

Mechanism

Partial agonist at dopamine D2 and serotonin 5-HT1A, antagonist at 5-HT2A.

Uses

Schizophrenia, mania in bipolar disorder, adjunct in depression.

Dosing

No dose is given in the chapters. See the BNF.

Side effects

Akathisia, insomnia, nausea, restlessness; low prolactin and metabolic effect compared with others; impulse-control problems.

Interactions

CYP2D6 and CYP3A4 inhibitors increase levels; inducers lower levels.

Contraindications and cautions

Caution in cardiovascular disease, epilepsy, dementia

Monitoring

Weight, glucose, lipids, akathisia

Pregnancy and breastfeeding

Use if benefit outweighs risk

Renal and hepatic impairment

No adjustment

Overdose and reversal

Supportive; activated charcoal early

Special advice

Monitor weight, glucose and lipids; ask about impulsive behaviours such as gambling.

More from the textbook: uses, cautions and other points
Where it is discussed in the book